EP2009056381 URINARY GM2 ACTIVATOR PROTEIN AS A MARKER OF ACUTE RENAL FAILURE OR THE RISK OF DEVELOPING ACUTE RENAL FAILURE

1. (WO2010136059) URINARY GM2 ACTIVATOR PROTEIN AS A MARKER OF ACUTE RENAL FAILURE OR THE RISK OF DEVELOPING ACUTE RENAL FAILURE

Latest bibliographic data on file with the International Bureau

Pub. No.:		WO/2010/136059		International Application No.:		PCT/EP2009/056381
Publication Date:		02.12.2010		International Filing Date:		26.05.2009

IPC:

G01N 33/50 (2006.01)

Applicants:

UNIVERSIDAD DE SALAMANCA [ES/ES]; Patio de Escuelas n.1 E-37008 Salamanca (ES) (For All Designated States Except US).
QUIROS LUIS, Yaremi [CU/ES]; (ES) (For US Only).
FERREIRA REDONDO, Laura [ES/ES]; (ES) (For US Only).
SANCHO MARTÍNEZ, Sandra María [ES/ES]; (ES) (For US Only).
GONZALEZ DE BUITRAGO ARRIERO, José Manuel [ES/ES]; (ES) (For US Only).
LOPEZ HERNANDEZ, Francisco José [ES/ES]; (ES) (For US Only).
LOPEZ NOVOA, José Miguel [ES/ES]; (ES) (For US Only)

Inventors:

QUIROS LUIS, Yaremi; (ES).
FERREIRA REDONDO, Laura; (ES).
SANCHO MARTÍNEZ, Sandra María; (ES).
GONZALEZ DE BUITRAGO ARRIERO, José Manuel; (ES).
LOPEZ HERNANDEZ, Francisco José; (ES).
LOPEZ NOVOA, José Miguel; (ES)

Agent:

PONS ARIÑO, Ángel; Glorieta Rubén Darío 4 E-28010 Madrid (ES)

Priority Data:

Title

(EN) URINARY GM2 ACTIVATOR PROTEIN AS A MARKER OF ACUTE RENAL FAILURE OR THE RISK OF DEVELOPING ACUTE RENAL FAILURE
(FR) PROTÉINE ACTIVATRICE DE GM2 URINAIRE EN TANT QUE MARQUEUR DE L'INSUFFISANCE RÉNALE AIGUË OU DU RISQUE DE DÉVELOPPER UNE INSUFFISANCE RÉNALE AIGUË

Abstract:

(EN)The invention relates to a method of determining the risk of developing acute renal failure (ARF) in an individual, or of determining an ARF, and a method of predicting the progression of an ARF, by detecting and/or quantifying the protein Ganglioside GM2 Activator Protein (GM2AP). The failure can be due to the administration of at least one nephrotoxic agent, wherein the nephrotoxic agent can be an aminoglycoside antibiotic as for example gentamicin.
(FR)L'invention concerne un procédé permettant de déterminer le risque de développer une insuffisance rénale aiguë (IRA) chez un individu ou permettant de déterminer une IRA, et un procédé permettant de prévoir la progression d'une IRA, par la détection et/ou la quantification de la protéine activatrice de ganglioside GM2 (GM2AP). L'insuffisance peut être due à l'administration d'au moins un agent néphrotoxique, l'agent néphrotoxique pouvant être un antibiotique aminoglycoside, par exemple de la gentamicine.

Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Publication Language:	English (EN)
Filing Language:	English (EN)